세계의 뉴포젠(필그라스팀) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Neupogen (filgrastim) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,290,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,091,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,893,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

뉴포젠(필그라스팀) 시장 규모는 향후 몇 년간 강한 성장세를 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 비용 효율적인 호중구 감소증 치료에 대한 수요 증가, 신흥 시장의 의료 서비스 접근성 확대, 바이오시밀러 보급에 대한 정부 지원 강화, 맞춤형 의약품에 대한 관심 증가, 고령 인구 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 바이오시밀러에 대한 연구 개발 투자 증가, 호중구 감소증 치료제 전달 시스템의 발전, 종양학 의약품 상용화를 위한 파트너십 증가, 환자의 경제적인 부담 경감 프로그램에 대한 관심 증가, 차세대 G-CSF 제품 개발 등이 있습니다.

다양한 질병의 유병률이 증가함에 따라 향후 몇 년 동안 뉴포젠(필그라스팀) 시장이 성장할 것으로 예상됩니다. 감염, 유전적 요인, 환경적 영향, 생활 습관 등으로 인한 질병은 인구 고령화, 앉아있는 생활 방식, 오염, 잘못된 식습관 등의 요인으로 인해 더욱 널리 퍼지고 있습니다. 뉴포젠(필그라스팀)은 호중구 생성을 촉진하여 면역력이 약해진 환자의 감염에 대항하는 면역 체계의 능력을 강화함으로써 화학요법 유발성 호중구 감소증의 관리에 중요한 역할을 합니다. 이는 입원 횟수를 줄이고 지속적인 암 치료를 가능하게 하는 데 필수적입니다. Allergy UK에 따르면, 2022년 영국에서 2,100만 명 이상의 사람들이 알레르기로 고통을 받았으며, 이 숫자는 더 증가할 것으로 예상됩니다. 또한 2025년까지 영국에서 약 350만 명의 사람들이 암으로 살게 될 것으로 예상되어, 뉴포젠과 같은 치료제의 필요성이 점점 더 커지고 있습니다. 이러한 동향은 앞으로 뉴포젠(필그라스팀)의 수요를 크게 촉진할 것입니다.

정부의 의료 연구 및 개발 지원 정책은 뉴포젠(필그라스팀) 시장을 촉진할 것으로 예상됩니다. 전 세계 정부는 의료 연구 자금 지원과 생명과학 제조업 확장을 통해 의료 치료제의 접근성을 개선하는 데 점점 더 집중하고 있습니다. 예를 들어, 2022년 영국 정부는 NHS 주도의 새로운 진단 및 치료법 연구 지원을 위해 2억 6,000만 파운드의 자금을 투입하고 생명과학 제조업 확장을 발표했습니다. 이러한 투자는 혁신을 촉진하고 고급 치료법 접근성을 높여, 뉴포젠과 같은 치료제의 성장에 직접적인 지원을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 뉴포젠(필그라스팀) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 뉴포젠(필그라스팀) 시장 : 성장률 분석
• 세계의 뉴포젠(필그라스팀) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 뉴포젠(필그라스팀) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 뉴포젠(필그라스팀) : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 뉴포젠(필그라스팀) 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 생물학적 제제
• 바이오시밀러
• 세계의 뉴포젠(필그라스팀) 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 화학요법 유발성 호중구 감소증
• 만성 호중구 감소증
• 기타
• 세계의 뉴포젠(필그라스팀) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 뉴포젠(필그라스팀) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 뉴포젠(필그라스팀) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 뉴포젠(필그라스팀) 시장 : 경쟁 구도
• 뉴포젠(필그라스팀) 시장 : 기업 프로파일
  • Amgen Inc.

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 뉴포젠(필그라스팀) 시장(2029년) : 새로운 기회를 제공하는 국가
• 뉴포젠(필그라스팀) 시장(2029년) : 새로운 기회를 제공하는 부문
• 뉴포젠(필그라스팀) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that promotes the production of white blood cells in the bone marrow. It is used to prevent infections in patients with neutropenia resulting from chemotherapy, bone marrow transplantation, or specific medical conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug types of neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are sourced from living organisms and require complex manufacturing processes to achieve targeted therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and other conditions. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The neupogen (filgrastim) market research report is one of a series of new reports from The Business Research Company that provides neupogen (filgrastim) market statistics, including neupogen (filgrastim) industry global market size, regional shares, competitors with a neupogen (filgrastim) market share, detailed neupogen (filgrastim) market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. This neupogen (filgrastim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1,727.1 million in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to rising demand for cost-effective neutropenia treatment, expansion of healthcare access in emerging markets, increased government support for biosimilar penetration, improved focus on personalized medicine, and a growing elderly population. Major trends in the forecast period include increasing research and development investments in biosimilars, advancements in drug delivery systems for neutropenia treatments, rising partnerships for oncology drug commercialization, a stronger focus on patient affordability programs, and the development of next-generation G-CSF products.

The increasing prevalence of various diseases is expected to drive the growth of the neupogen (filgrastim) market in the coming years. Diseases, whether caused by infections, genetic factors, environmental influences, or lifestyle choices, have become more prevalent due to factors such as aging populations, sedentary lifestyles, pollution, and poor dietary habits. Neupogen (filgrastim) plays a crucial role in managing chemotherapy-induced neutropenia by stimulating the production of neutrophils, which helps enhance the immune system's ability to combat infections in patients with weakened immunity. This is essential in reducing hospitalizations and allowing continuous cancer treatments. According to Allergy UK, over 21 million people in the UK suffered from allergies in 2022, a number expected to rise, and nearly 3.5 million people in the UK are projected to live with cancer by 2025, highlighting the growing need for treatments like neupogen. These trends will significantly drive demand for neupogen (filgrastim) in the future.

Government initiatives for research and development in healthcare are expected to propel the neupogen (filgrastim) market. Governments worldwide are increasingly focusing on funding healthcare research and expanding life sciences manufacturing to improve the availability of medical treatments. For example, in 2022, the UK government announced £260 million in funding to support NHS-led research into new diagnostics and treatments and to expand life sciences manufacturing. Such investments foster innovation and provide greater access to advanced therapies, which directly supports the growth of treatments like neupogen.

A key trend in the neupogen (filgrastim) market is the development of biosimilars, which offer cost-effective alternatives to the original drug while maintaining similar safety, efficacy, and structural characteristics. Filgrastim biosimilars are designed to mimic Neupogen, stimulating neutrophil production to treat chemotherapy-induced neutropenia. A notable development in this area occurred in November 2022, when Amneal Pharmaceuticals and Kashiv Biosciences launched Releuko (filgrastim-ayow), a biosimilar to Neupogen, in the U.S. Releuko provides both intravenous and subcutaneous formulations, offering flexibility in dosing and improving accessibility to essential treatments. This trend of biosimilars is increasing the affordability and availability of chemotherapy support medications, driving further growth in the Neupogen market.

The Key player operating in the neupogen (filgrastim) market is Amgen Inc.

North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neupogen (filgrastim) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neupogen (filgrastim) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neupogen (filgrastim) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neupogen (filgrastim) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neupogen (filgrastim) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neupogen (filgrastim) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Biologic; Biosimilar
• 2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neupogen (filgrastim) Market Characteristics

3. Neupogen (filgrastim) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Neupogen (filgrastim) Market Trends And Strategies

5. Neupogen (filgrastim) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Neupogen (filgrastim) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Neupogen (filgrastim) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Neupogen (filgrastim) Market Growth Rate Analysis
• 6.4. Global Neupogen (filgrastim) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Neupogen (filgrastim) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Neupogen (filgrastim) Total Addressable Market (TAM)

7. Global Neupogen (filgrastim) Market Pricing Analysis & Forecasts

8. Neupogen (filgrastim) Market Segmentation

• 8.1. Global Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologic
• Biosimilar
• 8.2. Global Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Induced Neutropenia
• Chronic Neutropenia
• Others
• 8.3. Global Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9. Global Neupogen (filgrastim) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Neupogen (filgrastim) Market Regional And Country Analysis

• 10.1. Global Neupogen (filgrastim) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Neupogen (filgrastim) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Neupogen (filgrastim) Market

• 11.1. Asia-Pacific Neupogen (filgrastim) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Neupogen (filgrastim) Market

• 12.1. China Neupogen (filgrastim) Market Overview
• 12.2. China Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Neupogen (filgrastim) Market

• 13.1. India Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Neupogen (filgrastim) Market

• 14.1. Japan Neupogen (filgrastim) Market Overview
• 14.2. Japan Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Neupogen (filgrastim) Market

• 15.1. Australia Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Neupogen (filgrastim) Market

• 16.1. South Korea Neupogen (filgrastim) Market Overview
• 16.2. South Korea Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Neupogen (filgrastim) Market

• 17.1. Western Europe Neupogen (filgrastim) Market Overview
• 17.2. Western Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Neupogen (filgrastim) Market

• 18.1. UK Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Neupogen (filgrastim) Market

• 19.1. Germany Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Neupogen (filgrastim) Market

• 20.1. France Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neupogen (filgrastim) Market

• 21.1. Eastern Europe Neupogen (filgrastim) Market Overview
• 21.2. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Neupogen (filgrastim) Market

• 22.1. North America Neupogen (filgrastim) Market Overview
• 22.2. North America Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Neupogen (filgrastim) Market

• 23.1. USA Neupogen (filgrastim) Market Overview
• 23.2. USA Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Neupogen (filgrastim) Market

• 24.1. Canada Neupogen (filgrastim) Market Overview
• 24.2. Canada Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Neupogen (filgrastim) Market

• 25.1. South America Neupogen (filgrastim) Market Overview
• 25.2. South America Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Neupogen (filgrastim) Market

• 26.1. Middle East Neupogen (filgrastim) Market Overview
• 26.2. Middle East Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Neupogen (filgrastim) Market

• 27.1. Africa Neupogen (filgrastim) Market Overview
• 27.2. Africa Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Neupogen (filgrastim) Market Competitive Landscape And Company Profiles

• 28.1. Neupogen (filgrastim) Market Competitive Landscape
• 28.2. Neupogen (filgrastim) Market Company Profiles
  • 28.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Neupogen (filgrastim) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Neupogen (filgrastim) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Neupogen (filgrastim) Market

32. Recent Developments In The Neupogen (filgrastim) Market

33. Neupogen (filgrastim) Market High Potential Countries, Segments and Strategies

• 33.1 Neupogen (filgrastim) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Neupogen (filgrastim) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Neupogen (filgrastim) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer